Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Journal of the National Cancer Institute

Volumn 97, Issue 5, 2005, Pages 339-346

  Shigematsu, Hisayuki ^a,h   Lin, Li ^c   Takahashi, Takao ^a   Nomura, Masaharu ^a   Suzuki, Makoto ^d   Wistuba, Ignacio I ^e   Fong, Kwun M ^f   Lee, Huei ^g   Toyooka, Shinichi ^h   Shimizu, Nobuyoshi ^h   Fujisawa, Takehiko ^d   Feng, Ziding ^c   Roth, Jack A ^e   Herz, Joachim ^b   Minna, John D ^a,b   Gazdar, Adi F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d CHIBA UNIVERSITY   (Japan)

^e UNIVERSITY OF TEXAS   (United States)

^f THE PRINCE CHARLES HOSPITAL   (Australia)

^g CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^h OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PROTEIN TYROSINE KINASE; VIRUS DNA;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EPITHELIUM TUMOR; ETHNIC DIFFERENCE; EXON; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; KRAS GENE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN DOMAIN; SMOKING; ADENOCARCINOMA; ASIAN; AUSTRALIA; CANCER STAGING; CARCINOMA; CAUCASIAN; CLINICAL TRIAL; DNA SEQUENCE; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENETICS; JAPAN; LUNG TUMOR; MISSENSE MUTATION; MULTICENTER STUDY; MUTATION; ONCOGENE RAS; PAPILLOMA VIRUS; PATHOLOGY; PROTO ONCOGENE; TAIWAN; UNITED STATES;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; AUSTRALIA; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; DNA, VIRAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE DUPLICATION; GENES, ERBB-1; GENES, RAS; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MUTAGENESIS, INSERTIONAL; MUTATION; MUTATION, MISSENSE; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PROTEIN-TYROSINE KINASES; SEQUENCE ANALYSIS, DNA; TAIWAN; UNITED STATES;

EID: 20044364940     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji055     Document Type: Article

References (38)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al.; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004;54: 8-29.
2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
3. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004;291:1763-8.
4. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999;118:1136-52.
5. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res 1994;14:261-7.
6. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998;1378: F21-59.
7. Minna JD, Gazdar AF, Sprang SR, Herz J. Cancer. A bull's eye for targeted lung cancer therapy. Science 2004;304:1458-61.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
9. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
10. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800-5.
11. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr., Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8.
12. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62: 5749-54.
13. Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003;21:2094-100.
14. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003;21:2237-46.
15. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
16. Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 2003;42:35-41.
17. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
18. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
19. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-11.
20. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
21. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer 2004;44:221-30.
22. Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, Yang SC, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92:1525-30.
23. Cheng YW, Chiou HL, Sheu GT, Hsieh LL, Chen JT, Chen CY, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001;61:2799-803.
24. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
25. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumours. 3rd ed. New York (NY): Springer-Verlag; 1999.
26. Kim DW, Lu B, Hallahan DE. Receptor tyrosine kinase inhibitors as antiangiogenic agents. Curr Opin Investig Drugs 2004;5:597-604.
27. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-82.
28. Gazdar AF, Shigematsu H, Herz J, Minna JD. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med 2004;10: 481-6.
29. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA Jr. HER2/neu expression in malignant lung tumors. Semin Oncol 2002;29:51-8.
30. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41:S29-42.
31. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991;83:1024-7.
32. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
33. Barnes CJ, Kumar R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Metastasis Rev 2003;22:301-7.
34. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4:361-70.
35. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene 2002;21:6898-907.
36. Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999;8:297-302.
37. Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001;61:4350-6.
38. Toyooka S, Tsuda T, Gazdar AF. The TP 53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003;21:229-39.